Elan will spend $1 billion of the $3.25 billion one-off payment it is receiving from Biogen Idec for the return of rights to the blockbuster multiple sclerosis drug Tysabri to buy back around a 16% stake in the Irish company.
Elan will spend $1 billion of the $3.25 billion one-off payment it is receiving from Biogen Idec for the return of rights to the blockbuster multiple sclerosis drug Tysabri to buy back around a 16% stake in the Irish company.
Elan today released limited additional information on how it intends to use the proceeds of the transaction, which it announced...
Create an account to read this article
Already a subscriber?
Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.
The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.
Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.
The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.
Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.
